GWAS of Diabetic Nephropathy: Is the GENIE out of the Bottle?

article has not abstract

Vyšlo v časopise: GWAS of Diabetic Nephropathy: Is the GENIE out of the Bottle?. PLoS Genet 8(9): e32767. doi:10.1371/journal.pgen.1002989
Kategorie: Perspective
prolekare.web.journal.doi_sk: https://doi.org/10.1371/journal.pgen.1002989

Souhrn

article has not abstract

Zdroje

1. Ismail-BeigiF, CravenT, BanerjiMA, BasileJ, CallesJ, et al. (2010) Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial. Lancet 376: 419–430.

2. GersteinHC, MillerME, ByingtonRP, GoffDCJr, BiggerJT, et al. (2008) Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 358: 2545–2559.

3. PatelA, MacMahonS, ChalmersJ, NealB, BillotL, et al. (2008) Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 358: 2560–2572.

4. HallerH, ItoS, IzzoJLJr, JanuszewiczA, KatayamaS, et al. (2011) Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes. N Engl J Med 364: 907–917.

5. ReavenPD, MoritzTE, SchwenkeDC, AndersonRJ, CriquiM, et al. (2009) Intensive glucose-lowering therapy reduces cardiovascular disease events in veterans affairs diabetes trial participants with lower calcified coronary atherosclerosis. Diabetes 58: 2642–2648.

6. Writing Team for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group (2003) Sustained effect of intensive treatment of type 1 diabetes mellitus on development and progression of diabetic nephropathy: the Epidemiology of Diabetes Interventions and Complications (EDIC) study. JAMA 290: 2159–2167.

7. SeaquistER, GoetzFC, RichS, BarbosaJ (1989) Familial clustering of diabetic kidney disease. Evidence for genetic susceptibility to diabetic nephropathy. N Engl J Med 320: 1161–1165.

8. BögerC, HeidI (2011) Chronic kidney disease: novel insights from genome wide association studies. Kidney Blood Press Res 34: 27–36.

9. SandholmN, SalemRM, McKnightAJ, BrennanEP, ForsblomC, et al. (2012) New susceptibility loci associated with kidney disease in type 1 diabetes. PLoS Genet 8: e1002921 doi:10.1371/journal.pgen.1002921.

10. VeikkolainenV, NaillatF, RailoA, ChiL, ManninenA, et al. (2012) ErbB4 modulates tubular cell polarity and lumen diameter during kidney development. J Am Soc Nephrol 23: 112–122.

11. EllisJW, ChenMH, FosterMC, LiuCT, LarsonMG, et al. (2012) Validated SNPs for eGFR and their associations with albuminuria. Hum Mol Genet 21: 3293–3298.

12. PlachaG, CananiLH, WarramJH, KrolewskiAS (2005) Evidence for different susceptibility genes for proteinuria and ESRD in type 2 diabetes. Adv Chronic Kidney Dis 12: 155–169.

13. BögerC, ChenMH, TinA, OldenM, KöttgenA, de BoerIH, et al. (2011) CUBN is a Gene Locus for Albuminuria. J Am Soc Nephrol 22: 555–570.

14. KöttgenA, PattaroC, BögerCA, FuchsbergerC, OldenM, et al. (2010) New loci associated with kidney function and chronic kidney disease. Nat Genet 42: 376–384.

15. PattaroC, KottgenA, TeumerA, GarnaasM, BogerCA, et al. (2012) Genome-wide association and functional follow-up reveals new loci for kidney function. PLoS Genet 8: e1002584 doi:10.1371/journal.pgen.1002584.

16. BögerC, GorskiM, LiM, HoffmannM, HuangC, et al. (2011) Association of eGFR-related loci identified by GWAS with incident CKD and ESRD. PLoS Genet 7: e1002292 doi:10.1371/journal.pgen.1002292.

17. KaoWH, KlagMJ, MeoniLA, ReichD, Berthier-SchaadY, et al. (2008) MYH9 is associated with nondiabetic end-stage renal disease in African Americans. Nat Genet 40: 1185–1192.

18. KoppJB, SmithMW, NelsonGW, JohnsonRC, FreedmanBI, et al. (2008) MYH9 is a major-effect risk gene for focal segmental glomerulosclerosis. Nat Genet 40: 1175–1184.

19. StanescuHC, Arcos-BurgosM, MedlarA, BockenhauerD, KöttgenA, et al. (2011) Risk HLA-DQA1 and PLA(2)R1 alleles in idiopathic membranous nephropathy. N Engl J Med 364: 616–626.

20. GharaviAG, KirylukK, ChoiM, LiY, HouP, et al. (2011) Genome-wide association study identifies susceptibility loci for IgA nephropathy. Nat Genet 43: 321–327.

21. LyonsPA, RaynerTF, TrivediS, HolleJU, WattsRA, et al. (2012) Genetically distinct subsets within ANCA-associated vasculitis. N Engl J Med 367: 214–223.

22. GenoveseG, FriedmanDJ, RossMD, LecordierL, UzureauP, et al. (2010) Association of trypanolytic ApoL1 variants with kidney disease in African Americans. Science 329: 841–845.

23. RemuzziG, BenigniA, RemuzziA (2006) Mechanisms of progression and regression of renal lesions of chronic nephropathies and diabetes. J Clin Invest 116: 288–296.

24. SteinkeJM, SinaikoAR, KramerMS, SuissaS, ChaversBM, et al. (2005) The early natural history of nephropathy in type 1 diabetes: III. Predictors of 5-year urinary albumin excretion rate patterns in initially normoalbuminuric patients. Diabetes 54: 2164–2171.

25. PerkinsBA, FicocielloLH, RoshanB, WarramJH, KrolewskiAS (2010) In patients with type 1 diabetes and new-onset microalbuminuria the development of advanced chronic kidney disease may not require progression to proteinuria. Kidney Int 77: 57–64.